Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Tisagenlecleucel, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Patients With Primary Central Nervous System Lymphoma

NCT04134117 is registered in ClinicalTrials.gov with Matthew J. Frigault, M.D. as lead sponsor.

NCT NCT04134117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04134117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Tisagenlecleucel, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Patients With Primary Central Nervous System Lymphoma
Lead sponsor
Matthew J. Frigault, M.D.
Phase
Phase 1
Overall status
Completed
Start date
January 1, 2019
Completion date
April 14, 2022
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary cns lymphoma, refractory primary cns lymphoma, relapsed primary cns lymphoma